Can a Multi-Drug combo outsmart resistant lymphoma?
NCT ID NCT03440567
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This phase I trial is testing a combination of drugs—avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy—in people with diffuse large B-cell lymphoma or mantle cell lymphoma that has returned or not responded to treatment. The goal is to find the safest dose and see how well the combination works. Participants will also receive an autologous stem cell transplant as part of the treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy (etoposide phosphate, carboplatin, ifosfamide), followed by autologous stem cell transplantation.
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat lymphomas that have returned or stopped responding to standard therapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The combination may cause significant side effects, and it is not yet known if it will be more effective than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Combination therapy aims to outsmart tough lymphoma
- New combo approach aims to boost CAR-T success in tough lymphoma
- New drug duo takes on tough lymphoma
- New combo attack on lymphoma shows promise in early trial